17-amino-3,6,9,12,15-pentaoxaheptadecane | 1159688-32-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 17-amino-3,6,9,12,15-pentaoxaheptadecane
• 英文别名: 3,6,9,12,15-pentaoxaheptadecan-1-amine；4,7,10,13,16-pentaoxa-1-azaoctadecane；2-[2-[2-[2-(2-Ethoxyethoxy)ethoxy]ethoxy]ethoxy]ethanamine
• CAS: 1159688-32-0
• 化学式: C₁₂H₂₇NO₅
• 分子量: 265.35
• InChiKey: AWKGXTCDNRRIFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  18
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  17-amino-3,6,9,12,15-pentaoxaheptadecane 、 N-叔丁氧羰基-4-哌啶酮 在 titanium(IV) isopropylate 、 sodium cyanoborohydride 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  [35S]GTPγS binding studies of amphiphilic drugs-activated Gi proteins: A caveat

  摘要：

  This paper documents a serious problem met during the testing of Gi protein-activating properties of a new series of synthetic compounds by measuring the induced binding of [(35)S]GTP gamma S to different subtypes of Gi protein. The problem arose from the strong affinity between [(35)S]GTP gamma S and the tested compounds, that are characterized by several (2-4) positive charges and high lipophilicity. Apparently, such affinity yields insoluble, labelled complexes that, also in the absence of Gi protein, are retained on the filters and give rise to false positive results. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.097

文献信息

• [EN] BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE<br/>[FR] PYRIMIDINES SUBSTITUÉES BIFONCTIONNELLES EN TANT QUE MODULATEURS DU PROTÉOLYSE DE FAK
  申请人：UNIV YALE

  公开号：WO2020023851A1

  公开（公告）日：2020-01-30

  The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为调节焦粘附激酶（FAK）或蛋白酪氨酸激酶2（PTK2）的调节剂。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体结合到相应的E3泛素连接酶，另一端为结合目标蛋白的基团，使目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• Nucleotide analogues
  申请人：Singular Genomics Systems, Inc.

  公开号：US10738072B1

  公开（公告）日：2020-08-11

  Disclosed herein, inter alia, are compounds, compositions, and methods of using the same for the sequencing of a nucleic acid.

  本文特别披露了用于核酸测序的化合物、组合物和使用方法。
• [EN] INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS<br/>[FR] DÉRIVÉS D'INDOLE EN TANT QU'AGENTS DE DÉGRADATION DES RÉCEPTEURS DES ŒSTROGÈNES
  申请人：ARVINAS INC

  公开号：WO2018053354A1

  公开（公告）日：2018-03-22

  The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DE KINASE DU FOIE FŒTAL
  申请人：ARVINAS INC

  公开号：WO2018118598A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of FLT3 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein FLT3, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of the target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.